对低血压和低动力性脱节的计算机分析,以改善对帕金森病的诊断
Justyna Skibińska1,2, Jiri Hosek1
1Faculty of Electrical Engineering and Communication, Brno University of Technology, Technicka 12, Brno, 61600, Czechia.
Heliyon
|November 1, 2023
概括
这项研究引入了一种通过分析语音和面部运动来诊断帕金森病 (PD) 的新方法. 将音频和视频数据合并实现了83%的准确性,提供了一个潜在的mHealth解决方案,以更轻松地监测患者.
科学领域:
- 神经学 神经学
- 生物医学工程 生物医学工程
- 计算机科学 计算机科学
背景情况:
- 人口老龄化需要对像帕金森病 (PD) 这样的神经退行性疾病提供可访问的诊断工具.
- 目前的PD诊断涉及耗时,不频繁的医院访问和临床检查.
- 需要方便的远程监控解决方案来改善患者的生活质量.
研究的目的:
- 探索用于PD诊断的低血压和低动力性失联症的计算机化分析的融合.
- 开发一种新的PD检测方法,集成到mHealth系统中.
- 为早期发现和管理帕金森病提供可访问的工具.
主要方法:
- 招募了73名PD患者和46名健康对照人进行数据收集.
- 录制参与者使用麦克风和摄像头执行语音/语音任务.
- 分析了使用XGBoost.模拟的声学信号 (声声,发音,表情) 和面部标志性运动.
主要成果:
- 声学分析为PD诊断提供了77%的平衡准确性;面部分析达到81%的准确性.
- 两种方法的融合导致了83%的平衡精度 (88%的灵敏度,78%的特异性).
- 舌头旋转成为最有信息的演讲练习; 鉴定出低血症的特征性面部肌肉运动.
结论:
- 多模式方法,整合语音和面部分析,检测PD高达83%的准确性.
- 这种计算机支持的方法可以作为神经病学家的辅助工具.
- 拟议的mHealth解决方案为患者和临床医生提供了一种方便的方法来管理帕金森病.
相关概念视频
Parkinson's Disease: Treatment
281
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
281
Parkinson's Disease: Overview
564
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
564


